Neuphoria Therapeutics (NEUP) Operating Expenses (2023 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Operating Expenses of $1.2 million for Q1 2026, down 59.92% year-over-year from $3.0 million in Q1 2025, and down 70.16% quarter-over-quarter from $4.1 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Operating Expenses (2023 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Operating Expenses for 4 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses fell 59.92% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $16.7 million (up 1.9% YoY), while the FY2025 annual figure was $16.8 million, down 6.23% from the prior year.
- Operating Expenses eased to $1.2 million in Q1 2026 per NEUP's latest filing, from $4.1 million in the prior quarter.
- Across five years, Operating Expenses topped out at $5.8 million in Q2 2025 and bottomed at $1.2 million in Q1 2026.
- Historically, Operating Expenses has averaged $4.1 million across 4 years, with a median of $4.4 million in 2024.
- Annual changes were most pronounced in 2025 — Operating Expenses soared 58.44% — and 2026, when it sank 59.92%.
- Neuphoria Therapeutics' Operating Expenses stood at $4.6 million in 2023, then fell by 4.1% to $4.4 million in 2024, then fell by 6.99% to $4.1 million in 2025, then plunged by 70.16% to $1.2 million in 2026.
- Business Quant data shows NEUP's Operating Expenses at $1.2 million in Q1 2026, $4.1 million in Q4 2025, and $5.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Neuphoria Therapeutics | 21.37 Mn | 1.93 Mn | - | 1.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.21 Mn |
| Dec 31, 2025 | 4.06 Mn |
| Sep 30, 2025 | 5.65 Mn |
| Jun 30, 2025 | 5.82 Mn |
| Mar 31, 2025 | 3.02 Mn |
| Dec 31, 2024 | 4.37 Mn |
| Sep 30, 2024 | 3.57 Mn |
| Jun 30, 2024 | 5.48 Mn |
| Mar 31, 2024 | 2.39 Mn |
| Dec 31, 2023 | 4.55 Mn |
| Sep 30, 2023 | 5.47 Mn |